Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMR Bio-Manguinhos Immunogenicity and Safety in Children
NCT01991899Phase 3Completed
- Sponsor
- Immunobiological Technology Institute
- Start
- Feb 2015
- Primary completion
- Dec 2015
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MMR vaccine in measles, mumps and rubella (2 arms), sponsored by Immunobiological Technology Institute. Primary endpoints: Immunogenicity comparing the 3 lots of MMR vaccine produced totally in Brazil and reference vaccine at 30 days, Safety at 30 days and 1 more. Started Feb 2015; status: completed.
02
Drugs
MMR vaccine
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on NCT01991899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01991899.